TriSalus Life Sciences, Inc. (TLSI)
TLSI moved a median of 0.00% 30 minutes after news, and +0.23% by the close. How TLSI actually reacts to news — the realized, point-in-time move the market made, measured across 344 labeled events over the last three years with zero look-ahead.
TLSI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 297 |
| 30-min | 0.00% | 48% | 315 |
| 60-min | +0.16% | 53% | 327 |
| to close | +0.23% | 54% | 344 |
| Middle 50% of TLSI reactions | -1.76% to +2.91% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 344 |
Half of all TriSalus Life Sciences, Inc. news events land between -1.76% and +2.91% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TLSI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.11% | 40% | +0.31% |
| Coverage initiations | 24 | 0.00% | 46% | -1.46% |
| Rating reiterations | 13 | -0.26% | 31% | +0.31% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how TLSI ranks against every other measured name →
That’s how TLSI usually reacts — get an email when it moves on news →Email me when TLSI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TLSI's baseline. Nothing else.
Recent TLSI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call | Press release | Business Wire | — | — | |
| Form 8-K TriSalus Life Sciences, For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -6.57% | -13.49% | |
| TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization | Press release | Business Wire | -6.57% | -13.49% | |
| TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference | Press release | Business Wire | +1.51% | +4.23% | |
| Form 10-Q TriSalus Life Sciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.85% | +13.56% | |
| Form 8-K TriSalus Life Sciences, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | +13.56% | |
| TriSalus Life Sciences Reports Second Quarter 2026 Results | Press release | Business Wire | -3.85% | +13.56% | |
| TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference | Press release | Business Wire | +0.46% | +4.11% | |
| TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call | Press release | Business Wire | -1.74% | -0.23% | |
| TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer | Press release | Business Wire | +2.98% | +5.97% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TriSalus Life Sciences, Inc. (TLSI) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +1.92% | +2.56% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.46% | -3.21% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.31% | -0.94% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.44% | +7.63% | |
| TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +1.88% | +6.90% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (TLSI) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.00% | +0.63% | |
| TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | -0.92% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.30% | -2.13% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.30% | -2.13% | |
| Form 8-K TriSalus Life Sciences, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -2.82% | +8.06% | |
| Form 10-Q TriSalus Life Sciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -11.94% | -25.83% | |
| Form 8-K TriSalus Life Sciences, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -11.94% | -25.83% | |
| Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance | Press release | Business Wire | +1.09% | -0.87% | |
| TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth | Press release | Business Wire | -11.94% | -25.83% | |
| TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors | Press release | Business Wire | +0.00% | +2.90% | |
| Form 8-K TriSalus Life Sciences, For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +0.23% | |
| TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call | Press release | Business Wire | +1.12% | -4.27% | |
| TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting | Press release | Business Wire | +1.19% | +0.48% | |
| Form 8-K TriSalus Life Sciences, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -0.26% | +4.21% | |
| TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer | Press release | Business Wire | — | +2.63% | |
| Form ARS TriSalus Life Sciences, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +6.67% | |
| Form DEF 14A TriSalus Life Sciences, For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +6.67% | |
| Form DEFA14A TriSalus Life Sciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +6.67% | |
| TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models | Press release | Business Wire | -0.25% | -4.47% | |
| Form S-8 TriSalus Life Sciences, | SEC filing · Form S-8 | SEC EDGAR | +2.94% | -2.12% | |
| Form 10-K TriSalus Life Sciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.53% | -5.00% | |
| Form 8-K TriSalus Life Sciences, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +0.53% | -5.00% | |
| TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance | Press release | Business Wire | +0.53% | -5.00% | |
| TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call | Press release | Business Wire | -2.87% | -3.58% | |
| Form 8-K TriSalus Life Sciences, For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -2.31% | -8.78% | |
| TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering | Press release | Business Wire | +4.49% | +11.00% | |
| TriSalus Life Sciences Proposes Public Offering | Press release | Business Wire | +4.49% | +11.00% | |
| Form 8-K TriSalus Life Sciences, For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | -3.42% | |
| TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors | Press release | Business Wire | +1.50% | -3.42% | |
| Form 8-K TriSalus Life Sciences, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | +0.51% | |
| TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance | Press release | Business Wire | -0.69% | +0.51% | |
| Form EFFECT TriSalus Life Sciences, | SEC filing · Form EFFECT | SEC EDGAR | -1.71% | +5.06% | |
| TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 | Press release | Business Wire | -1.71% | +5.06% | |
| TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™ | Press release | Business Wire | +0.11% | +2.22% | |
| TriSalus Life Sciences to Participate in Upcoming Investor Conferences | Press release | Business Wire | +1.15% | +1.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TLSI section they belong to.
Where else TLSI is measured.
TLSI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is TriSalus Life Sciences, Inc.'s median reaction calculated?
Every labeled TLSI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 344 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of TLSI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TLSI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.